Glenmark to launch anti-hypertension drug in US, gets USFDA nod

Tags: Companies
Glenmark Pharmaceuticals will launch generic version of anti-hypertension drug telmisartan tablets in the US market following receipt of approval from the country's health regulator.

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Ltd has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets, the company said in a filing to the BSE.

"Glenmark will commence distribution of the product immediately," it added.

The approval is for the 20 mg, 40 mg and 80 mg tablets.

Telmisartan tablets are Glenmark's generic version of Boehringer Ingelheim's Micardis. Telmisartan is indicated for the treatment of hypertension.

For the 12-month period ended March 2014, Telmisartan garnered annual sales of USD 250 million, according to IMS Health, the company said.

Glenmark's current portfolio consists of 92 products authorised for distribution in the US market and 73 ANDAs are pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 595.60 per scrip in the mid-day trade, up 1.09 per cent from the previous close on the BSE.

EDITORIAL OF THE DAY

  • India is taking China head on with its Japan aided Asia–Africa growth corridor

    Collaborative pursuit of Asia–Africa growth corridor in partnership with Japan is significant in more ways than one.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Cut & Thrust: Islam’s dance of death

It is a short walk between victim hood and blood ...

Ananda Majumdar

Walking the tightrope

For perhaps the most voluble antagonist of Narendra Modi at ...

Zehra Naqvi

Mindful meditation in everyday life

Amid the vast multitude of tasks and huge amounts of ...